PMID- 24164533
OWN - NLM
STAT- MEDLINE
DCOM- 20160322
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 55
IP  - 7
DP  - 2014 Jul
TI  - Peripheral blood CD4/CD19 cell ratio is an independent prognostic factor in 
      classical Hodgkin lymphoma.
PG  - 1596-601
LID - 10.3109/10428194.2013.854889 [doi]
AB  - Classical Hodgkin lymphoma (cHL) is characterized by the presence of tumoral 
      cells in a rich background of T and B cells, macrophages and other inflammatory 
      cells. The contribution of these non-tumoral cells to the pathogenesis of HL is 
      still poorly understood. In our study we evaluated the prognostic significance of 
      peripheral blood B, T and natural killer (NK) cells at diagnosis in 118 
      immunocompetent patients with cHL treated at our institution between January 2006 
      and December 2010. Fifty-four (46%) were male and 64 (54%) female. Median age at 
      diagnosis was 33 years (range 15-82), and 71 patients (60%) presented an advanced 
      stage (IIB-IV), 54 (46%) had bulky disease and 55 (47%) presented B symptoms. At 
      the end of treatment, 94 patients (80%) had a complete response (CR) and 24 (20%) 
      had a partial response. After a median follow-up of 54 months, 18 patients (15%) 
      had relapsed. The variables that had a negative impact on progression-free 
      survival (PFS) at univariate analysis were advanced stage, bone marrow 
      involvement, International Prognostic Score (IPS) >/= 3, positive interim positron 
      emission tomography (int-PET), NK cells < 200/muL, CD19 cells < 85/muL, CD3/CD19 
      ratio >/= 13 and CD4/CD19 ratio >/= 10. At multivariate analysis, advanced stage, 
      positive int-PET and CD4/CD19 ratio >/= 10 were independent prognostic factors of 
      PFS. New biological markers could be predictive of the response to treatment and 
      survival in cHL. A CD4/CD19 ratio >/= 10 seems to be associated with a worse 
      outcome.
FAU - Gaudio, Francesco
AU  - Gaudio F
AD  - Hematology Section, Department of Emergency and Organ Transplantation, University 
      of Bari Medical School , Bari , Italy.
FAU - Perrone, Tommasina
AU  - Perrone T
FAU - Mestice, Anna
AU  - Mestice A
FAU - Curci, Paola
AU  - Curci P
FAU - Giordano, Annamaria
AU  - Giordano A
FAU - Delia, Mario
AU  - Delia M
FAU - Pastore, Domenico
AU  - Pastore D
FAU - Specchia, Giorgina
AU  - Specchia G
LA  - eng
PT  - Journal Article
DEP - 20140204
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, CD19)
RN  - 0 (CD4 Antigens)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/metabolism
MH  - Antigens, CD19/metabolism
MH  - CD4 Antigens/metabolism
MH  - Female
MH  - Hodgkin Disease/*diagnosis/*immunology/mortality/therapy
MH  - Humans
MH  - Immunophenotyping
MH  - Lymphocyte Count
MH  - Lymphocyte Subsets/*immunology/metabolism
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Positron-Emission Tomography
MH  - Prognosis
MH  - ROC Curve
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Hodgkin lymphoma
OT  - Lymphocytes
OT  - prognosis
EDAT- 2013/10/30 06:00
MHDA- 2016/03/24 06:00
CRDT- 2013/10/30 06:00
PHST- 2013/10/30 06:00 [entrez]
PHST- 2013/10/30 06:00 [pubmed]
PHST- 2016/03/24 06:00 [medline]
AID - 10.3109/10428194.2013.854889 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2014 Jul;55(7):1596-601. doi: 10.3109/10428194.2013.854889. Epub 
      2014 Feb 4.